U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Google Secures Pentagon AI Deal for Classified Projects 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
JERSEY, Channel Islands, May 09, 2017 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the UBS Global Healthcare Conference on Tuesday, May 23, 2017 at 10:30 a.m. Eastern Time at the Grand Hyatt New York. Also participating in the conference will be the Company’s Chief Financial Officer, Chris Lindop.
A webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.quotientbd.com. A webcast replay will be archived on the website for approximately 90 days.
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company's operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
CONTACT: Chris Lindop, Chief Financial Officer — [email protected]; +41 (0)799 61 69 38
